Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Paxmedica Inc (NQ: PXMD )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Paxmedica Inc

< Previous 1 2 3 4 Next >
Study Links Microbiome Composition to Autism Spectrum Disorder
Via Investor Brand Network
New Study Challenges Perception of Males Being More Susceptible to Autism
Via Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals Living with ASD
Via Investor Brand Network
Study Suggests Pediatric Autism Could Be Linked to Umbilical Cord Lipid Levels at Birth
Via Investor Brand Network
InvestorBrandNetwork Highlights PaxMedica Inc.’s (NASDAQ: PXMD) Video Release on Transformative ASD Study
Via Investor Brand Network
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
Via ACCESSWIRE
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Address Unmet ASD Needs
Via Investor Brand Network
Israeli Study Offers Hope to Sleeping Sickness Patients
Via Investor Brand Network
BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Files 8-K Following Nasdaq Compliance Achievement
Via Investor Brand Network
PaxMedica Inc. (NASDAQ: PXMD) Fireside Chat with CEO Howard Weisman Sheds Light on Company Achievements for ASD Therapy Pipeline
Via Investor Brand Network
Chinese Researchers Notch Major Milestone in Developing Gene Editing System Against Autism
Via Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) CEO Featured in Just-Released Fireside Chat Video
Via Investor Brand Network
Exposures Product Safety
PaxMedica Inc. (NASDAQ: PXMD) Completes Key Type-B FDA Meeting, Discussing Positive Results from PAX-HAT-301 Study
Via Investor Brand Network
Exposures Product Safety
PaxMedica Inc. (NASDAQ: PXMD) Closes Public Offering of Approximately $7 Million and Continues Pursuing ASD Pipeline
Via Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Featured in Recent H.C. Wainwright & Co. Research Report with ‘Buy’ Rating, $3 PT
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Study Shows Autistic People Have Lower Life Expectancy Than General Population
Via Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M
Via Investor Brand Network
PaxMedica Announces Closing of $7.0 Million Public Offering
Via ACCESSWIRE
BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Announces Pricing of $7M Public Offering
Via Investor Brand Network
PaxMedica Announces Pricing of $7.0 Million Public Offering
Via ACCESSWIRE
Study Examines Role of African Sleeping Sickness in Body Wasting
Via Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) News of FDA Type-B Meeting Shared in Syndicated Audio Broadcast
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Releases Q3 2023 Financial Report, Corporate Update
Via Investor Brand Network
Exposures Product Safety
PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update
Via ACCESSWIRE
PaxMedica Inc. (NASDAQ: PXMD) Is Hoping to Boost Patient Independence with Potential ASD Treatment Amid Growing Prevalence Rates
Via Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) CMO Featured in Latest Bell2Bell Podcast Release
Via Investor Brand Network
Exposures Product Safety
Study Finds Autism Compromises Sleep Quality, Physical Activity in Kids
Via Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Phase 2 Study Results Published in Peer-Reviewed Journal
Via Investor Brand Network
PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal
Via ACCESSWIRE
PaxMedica Inc. (NASDAQ: PXMD) PRV Sale Prospects Strengthened by Recent Industry Developments
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.